Einzeltreffer — DigiBib

New improved formulations are described, comprising at least one composition, with or without another composition (at least one second composition), in which the at least one composition, a first composition, is an inhibitor of lipid A deacetylase resulting in permeabilization of an outer membrane of a susceptible microorganism to which it is provided to. The at least one second composition may be a streptogramin. The first composition, alone or in combination with another, may be used to improve and/or treat a wide variety of bacterial infections, providing, on its own better efficacy, bioavailability, and/or pharmacokinetics, as compared with at least other or alternative inhibitors of lipid A deacetylase, as well as no expected cardiotoxicity. When provided to a susceptible microorganism as a combination described herein, the combination may be provided independently or may be provided together (co-combined in a same formulation, or in different formulations). Such combinations may also be provided via any route(s) of administration, and in any pharmaceutically acceptable form known, available, and/or suitable for use, such as to a subject in need thereof.

Titel:	Pristinamycin compositions, LpxC compositions, their improvements, and combinations thereof
Autor/in / Beteiligte Person:	Fleurir ABX, LLC
Link:	View record in USPTO Patent Grants (Volltext)
Veröffentlichung:	2024
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Grants Sprachen: English Patent Number: 11951,148 Publication Date: April 09, 2024 Appl. No: 17/498647 Application Filed: October 11, 2021 Assignees: FLEURIR ABX, LLC (Raleigh, NC, US) Claim: 1. A composition for utilization in a subject in need thereof having or suspected of having an aerobic bacteria susceptible to the composition, the composition comprising: an effective amount of an inhibitor of lipid A deacetylase, the inhibitor being one that inhibits lipid A deacetylase in the aerobic bacteria, and the effective amount of the inhibitor causing permeabilization of an outer membrane of the aerobic bacteria thereby compromising integrity of the aerobic bacteria, wherein the composition comprising the effective amount of the inhibitor is a pharmaceutically acceptable form of the composition and in a form suitable for administration of the composition to the subject in need thereof, the composition optionally including one or more pharmaceutically acceptable excipients for administration of the composition, wherein the composition, when causing permeabilization of the outer membrane of the aerobic bacteria, inhibits or prevents formation of the outer membrane of the aerobic bacteria, wherein the aerobic bacteria is one or more aerobic bacteria causing or suspected of causing an infection in the subject in need thereof, wherein the aerobic bacteria is Gram-negative and is targeted by the composition, wherein the composition is in the form of at least one of Formula I, Formula II, and Formula III, or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, in which Formula I is: [chemical expression included] and Formula II is: [chemical expression included] and Formula III is: [chemical expression included] wherein R 1 is any one of: [chemical expression included] wherein R 2 is any one of: [chemical expression included] and wherein R 3 is any one or more of: [chemical expression included] [chemical expression included] Claim: 2. The composition of claim 1 , wherein the infection is one or more of an infection selected from a group consisting of respiratory tract infection, systemic or blood infection, gastrointestinal infection, skin infection, genitourinary tract infection. Claim: 3. The composition of claim 1 , wherein the composition is administered orally to the subject in need thereof. Claim: 4. The composition of claim 1 , wherein the composition is administered intravenously to the subject in need thereof. Claim: 5. The composition of claim 1 , wherein the composition is administered by inhalation to the subject in need thereof. Claim: 6. The composition of claim 1 , wherein the subject in need thereof is further provided with another antibacterial agent. Claim: 7. The composition of claim 1 , wherein the composition having the effective amount of the inhibitor does not provide a cardiotoxic effect in the subject. Claim: 8. The composition of claim 1 , wherein the composition is assessed in relation to its area under the curve and Cmax. Claim: 9. The composition of claim 1 , wherein the one or more pharmaceutically acceptable excipients comprise one or more from a group consisting of a carrier, solvent, adjuvant, and diluent. Claim: 10. The composition of claim 1 , wherein the aerobic bacteria is resistant to an antibiotic from another class of antibiotics. Claim: 11. The composition of claim 1 , wherein the aerobic bacteria is selected from one or more from a group consisting of Burkholderia spp., Coxiella burnetii, Escherichia coli, Klebsiella pneumoniae, Proteus spp., Acinetobacter baumanii, Haemophilus influenzae, Moraxella catarrhalis, Legionella pneumophila, Chlamydia pneumoniae, Mycoplasma pneumoniae, Pseudomonas aeruginosa, Francisella tularensis, Stenotrophomonas maltophila , and Yersinia pestis. Claim: 12. The composition of claim 1 further comprising a phosphodiesterase inhibitor for inhalation. Claim: 13. The composition of claim 1 further comprising sodium nitrite for inhalation. Patent References Cited: 8101640 January 2012 Anderson et al. ; 9539306 January 2017 Pace ; 9872884 January 2018 Pace ; 20040229955 November 2004 Anderson et al. ; 20110008467 January 2011 Sherman ; 20120283175 November 2012 Patten et al. ; 2014177468 September 2014 ; WO 2008154642 December 2008 ; WO 2011005355 January 2011 ; WO 2012031298 March 2012 ; WO 2012154204 November 2012 ; WO 2014160649 October 2014 Primary Examiner: Heard, Thomas S Attorney, Agent or Firm: Vander Molen, Monique A.

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Pristinamycin compositions, LpxC compositions, their improvements, and combinations thereof